Lyerly
David Lyerly, Radford, VA US
Patent application number | Description | Published |
---|---|---|
20160138009 | NUCLEIC ACID EXTRACTION USING ORGANIC SOLVENTS TO REMOVE INHIBITORS - Nucleic acid amplification tests have been widely used in clinical laboratories. Nucleic acid extraction from biological materials is challenging because different unfavorable substances may co-extract and inhibit downstream applications. The present invention relates to a composition of and a method for treating the sample prior, during or post extraction of nucleic acid. More specifically, the claimed invention relates to a composition of and a method for using low concentrations of common organic solvents to remove inhibitors of nucleic acid amplification. The present invention can be used for extracting nucleic acids (DNA/RNA) from bacteria, viruses, parasites, and other biological materials or matrices, including but not limit to, stool samples, body fluids, plants and cultures. The method is rapid, low-cost, and easy to use in a laboratory setting. The nucleic acid extracted in accordance with the invention can be used for nucleic acid amplification reactions. | 05-19-2016 |
David M. Lyerly, Radford, VA US
Patent application number | Description | Published |
---|---|---|
20110318240 | DEVICE AND METHOD FOR DETECTION OF ANALYTES - The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest. | 12-29-2011 |
20120276059 | FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE - disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of | 11-01-2012 |
20120276060 | FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE - disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of | 11-01-2012 |
20130052640 | CLOSTRIDIUM DIFFICILE DEHYDROGENASE AND TOXIN AS A BIOMARKER FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE AND DIFFERENTIATING CARRIER STATE FROM ACTIVE DISEASE - disease involves a range of clinical presentations ranging from carrier status with other causes of symptoms to mild and self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of | 02-28-2013 |
20130130281 | CYSTEINE PROTEASE Cwp84 (CD2787) AS A DIAGNOSTIC MARKER FOR CLOSTRIDIUM DIFFICILE - Accurate and fast detection of the presence of | 05-23-2013 |
20130273642 | DEVICE AND METHOD FOR DETECTION OF ANALYTES - The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest. | 10-17-2013 |
20130302813 | CELL WALL PROTEIN CwpV (CD0514) AS A DIAGNOSTIC MARKER FOR CLOSTRIDIUM DIFFICILE RIBOTYPE 027 - Accurate and rapid differentiation of the outbreak strain ribotype 027 from other possible | 11-14-2013 |
20140219966 | FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE - Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation. | 08-07-2014 |
20150044697 | OUTER MEMBRANE PROTEIN 18 AS A DIAGNOSTIC MARKER FOR CAMPYLOBACTER - Accurate and fast detection of the presence of | 02-12-2015 |
20150044698 | OUTER MEMBRANE PROTEIN 18 AS A DIAGNOSTIC MARKER FOR CAMPYLOBACTER - Accurate and fast detection of the presence of Campylobacter disease is important for the proper treatment of patients with Campylobacter infection. Present tests depend upon culture of viable bacteria and identification by microscopy, which requires care, skill, and two or more days for conclusive results. The current invention improves the ease of use and overcomes the limitations of loss of viability and delay inherent in Campylobacter bacterial culture and provides a more rapid alternative for the identification and diagnosis of Campylobacter and campylobacteriosis. The invention provides a new method of detecting Campylobacter by utilizing an outer membrane protein (OMP 18) to develop antibodies for use in immunoassays of bacterial cultures or human fecal samples. | 02-12-2015 |
20150204875 | DEVICE AND METHOD FOR DETECTION OF ANALYTES - The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest. | 07-23-2015 |
David Maxwell Lyerly, Blacksburg, VA US
Patent application number | Description | Published |
---|---|---|
20090253155 | Method For Diagnosing Irritable Bowel Syndrome and Monitoring Inflammatory Bowel Disease - A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease. | 10-08-2009 |
Herbert K. Lyerly, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20140377261 | VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. | 12-25-2014 |
Herbert Kim Lyerly, Chapel Hill, NC US
Patent application number | Description | Published |
---|---|---|
20110236907 | RADIOLABLED CYCLOPAMINE ASSAY FOR THE SMOOTHENED RECEPTOR - The present invention discloses novel methods for screening compositions for both agonist and antagonist activity on the smoothened receptor. The assay tests ligands on the activity of the receptor using a cyclopamine binding and ultra high receptor expression. | 09-29-2011 |
H. Kim Lyerly, Durham, NC US
Patent application number | Description | Published |
---|---|---|
20120094974 | SMOOTHENED RECEPTOR MODULATORS - The present invention relates, in general, to the Smoothened receptor and, in particular, to a method of modulating Smoothened receptor activity and to compounds and compositions suitable for use in such a method. | 04-19-2012 |
H. Kim Lyerly, Chapel Hill, NC US
Patent application number | Description | Published |
---|---|---|
20130005802 | TREATMENT OF WNT/FRIZZLED-RELATED DISEASES - Methods of treating Wnt/Frizzled-related diseases, comprising administering niclosamide compounds are provided. Methods of predicting whether a disease will respond to treatment with a niclosamide compound are also provided. | 01-03-2013 |
Joseph C. Lyerly, Florence, SC US
Patent application number | Description | Published |
---|---|---|
20140217249 | COLLAPSIBLE STAND ASSEMBLY - The present invention relates to a collapsible stand assembly. The stand includes four sets of strut members wherein each set of struts are rotationally connected at a midpoint and the lower ends of the strut members are rotationally connected to feet and the upper ends of the strut members are rotationally connected to brackets. A cross support member is rotationally connected at a first end of each bracket such that the second end of the cross support member can be secured to the other bracket on the same side of the stand at different locations to provide different widths and heights of the stand. Two sets of struts on opposite sides of the stand extend above the cross support members to create a stop to prevent structures supported by the stand, such as a cooler, from sliding off the stand when erected. | 08-07-2014 |
Larry L. Lyerly, Florence, SC US
Patent application number | Description | Published |
---|---|---|
20140217249 | COLLAPSIBLE STAND ASSEMBLY - The present invention relates to a collapsible stand assembly. The stand includes four sets of strut members wherein each set of struts are rotationally connected at a midpoint and the lower ends of the strut members are rotationally connected to feet and the upper ends of the strut members are rotationally connected to brackets. A cross support member is rotationally connected at a first end of each bracket such that the second end of the cross support member can be secured to the other bracket on the same side of the stand at different locations to provide different widths and heights of the stand. Two sets of struts on opposite sides of the stand extend above the cross support members to create a stop to prevent structures supported by the stand, such as a cooler, from sliding off the stand when erected. | 08-07-2014 |